Medtronic and IBM Partner to Transform Diabetes Management

By MedTech Intelligence Staff
No Comments

IBM’s Watson Health Unit is forming several collaborations to facilitate personalized health on a massive scale.

Medtronic and IBM’s Watson Health Unit are teaming up to provide personalized, more comprehensive and powerful data to diabetes management solutions, leveraging Medtronic’s diabetes devices and care management products with IBM’s Watson Health Cloud, which is a secure and open platform.

In a recent Medtronic press release:

The two companies also expect to develop near real-time, dynamic personalized care plans that provide decision support for health care providers and their patients with the goal of improving care efficiency and outcomes. IBM and Medtronic will also jointly explore ways to leverage IBM’s Watson platform to improve Medtronic and partners’ closed loop algorithms, which intend to mimic the function of a healthy pancreas. 

“We are building a secure, open innovation platform that could change the face of diabetes management,” said John E. Kelly III, IBM senior vice president, solutions portfolio and research. “Medtronic and IBM can marry the power of analytics, cognitive computing and patient engagement with the world’s most sophisticated diabetes management devices to truly change how people with diabetes live.”

IBM’s Watson Health Unit has announced other recent collaborations, including on Apple’s HealthKit and ResearchKit; and with Johnson & Johnson to monitor and enhance patient care prior to and following hip and knee replacements.

Related content: 

Digital Health Space Attracts Google, Nintendo, and now Apple
What Can Apps Do for Health?


Related Articles

  • Roberta Goode, president & CEO of Goode Compliance International, weighs in on the latest challenges medical device manufacturers are facing in risk management at the MedTech Intelligence HHE, Risk Assessment, & Recalls Conference in Washington, DC.

  • Medtronic Posts Higher-Than-Expected Q3 Profits

    The company’s heart devices such as implantable defibrillators, artificial valves and devices to treat atrial fibrillation, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit.

  • This month MedTech Intelligence will cover the diabetes market, along with technologies and solutions that are improving patient quality of life.

  • Purchasing Controls and Supplier Management

    A high degree of risk identification and management throughout the supply chain is what establishes a company as 'world class,' says Steve C de Baca - Senior VP, Global Quality & Regulatory, Beckman Coulter Diagnostics.

Leave a Reply

Your email address will not be published. Required fields are marked *